Evidence map›Paper›PMID 30470922›Full record

ArticleChemistry Central journal2018

Fabrication of 6-gingerol, doxorubicin and alginate hydroxyapatite into a bio-compatible formulation: enhanced anti-proliferative effect on breast and liver cancer cells.

Danushika C Manatunga, Rohini M de Silva, K M Nalin de Silva, Dulharie T Wijeratne, Gathsaurie Neelika Malavige, Gareth Williams

Open access · goldAbstract read
In one paragraph

Article in Chemistry Central journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Danushika C ManatungaDepartment of Chemistry, University of Colombo, Colombo, 00300, Sri Lanka.
Rohini M de SilvaDepartment of Chemistry, University of Colombo, Colombo, 00300, Sri Lanka. rohini@chem.cmb.ac.lk.ORCID http://orcid.org/0000-0003-0955-6366
K M Nalin de SilvaDepartment of Chemistry, University of Colombo, Colombo, 00300, Sri Lanka.
Dulharie T WijeratneCentre for Dengue Research, Department of Microbiology, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, 10250, Sri Lanka.
Gathsaurie Neelika MalavigeCentre for Dengue Research, Department of Microbiology, Faculty of Medical Sciences, University of Sri Jayewardenepura, Nugegoda, 10250, Sri Lanka.
Gareth WilliamsUCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK.
University of Colombo · LKUniversity of Sri Jayewardenepura · LKSri Lanka Institute of Nanotechnology · LKUniversity College London · GB

Funding

National Research Council Sri Lanka NRC 14-016
6 · The paper itself

Abstract

Ample attention has been devoted to the construction of anti-cancer drug delivery systems with increased stability, and controlled and targeted delivery, minimizing toxic effects. In this study we have designed a magnetically attractive hydroxyapatite (m-HAP) based alginate polymer bound nanocarrier to perform targeted, controlled and pH sensitive drug release of 6-gingerol, doxorubicin, and their combination, preferably at low pH environments (pH 5.3). They have exhibited higher encapsulation efficiency which is in the range of 97.4-98.9% for both 6-gingerol and doxorubicin molecules whereas the co-loading has accounted for a value of 81.87 ± 0.32%. Cell proliferation assays, fluorescence imaging and flow cytometric analysis, demonstrated the remarkable time and dose responsive anti-proliferative effect of drug loaded nanoparticles on MCF-7 cells and HEpG2 cells compared with their neat counter parts. Also, these systems have exhibited significantly reduced toxic effects on non-targeted, non-cancerous cells in contrast to the excellent ability to selectively kill cancerous cells. This study has suggested that this HAP based system is a versatile carrier capable of loading various drug molecules, ultimately producing a profound anti-proliferative effect.

Indexed as

6-GingerolDoxorubicinHEpG2HydroxyapatiteMCF-7

Identifiers

PMID30470922
PMCPMC6768026
OpenAlexW2901873009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.